All In Biotech

Drug Trial Radar · NCT01659502

Investigator's Initiated Phase II Study for Pancreatic Cancer Patients

Last checked: Nov 19, 2026Latest source record: Dec 5, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

10

Planned (sponsor's estimate)

Start

Dec 2013

Primary completion

Oct 2014

Sponsor

Lead sponsor
Tiltan Pharma Ltd.Industry
Sponsor type
Industry
First posted
Aug 7, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety and tolerability of TL-118 alone or in combination with pancreatic cancer chemotherapy.

Conditions

  • Pancreatic Cancer

Interventions

  • TL-118Drug

    TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Benefit MeasurementTime frame: Baseline up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hadassah Medical Center

    Jerusalem, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.